Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis
- PMID: 19701045
- DOI: 10.1097/AOG.0b013e3181b47217
Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients: a meta-analysis
Abstract
Objective: To appraise critically the diagnostic accuracy of cervicovaginal fetal fibronectin as a short-term predictor of preterm birth in patients with signs and symptoms of preterm labor.
Data sources: We searched MEDLINE, Current Contents, Index Medicus, EMBASE, the Cochrane Library, and syllabi from scientific meetings, and we performed manual searches of references from textbooks and of known primary and systematic review articles. We also contacted authors, experts on this subject, and the manufacturer.
Methods of study selection: We targeted cohort studies reporting data on the diagnostic accuracy of fetal fibronectin for the prediction of preterm birth within 7 days in symptomatic patients before 37 weeks of gestation. Case-control studies were excluded. The total analysis included 32 trials with 5,355 overall participants.
Tabulation, integration, and results: Two authors independently assessed methodological quality and constructed 2x2 tables for assessment of diagnostic measures. Pooled estimates of sensitivity, specificity, and likelihood ratios were obtained using a bivariate random effects model. Tests for publication bias and meta-regression were performed. Sensitivity analyses were performed for studies using different fetal fibronectin assays. The overall pooled estimates for sensitivity and specificity were 76.1% (95% confidence interval [CI] 69.1-81.9) and 81.9% (95% CI 78.9-84.5), respectively. Likelihood ratios for a positive and negative fetal fibronectin test were 4.20 (95% CI 3.53-4.99) and 0.29 (95% CI 0.22-0.38), respectively. Meta-regression analyses found that test accuracy was affected by prevalence, publication year, and blinding of studies. When subgroup analyses were performed for studies using the same assay, the results were similar.
Conclusion: The cervicovaginal fetal fibronectin assay has limited accuracy in predicting preterm birth within 7 days of sampling in symptomatic pregnant women.
Comment in
-
Fetal fibronectin as a short-term predictor of preterm birth in symptomatic patients.Obstet Gynecol. 2010 Jan;115(1):186-187. doi: 10.1097/AOG.0b013e3181c885ed. Obstet Gynecol. 2010. PMID: 20027059 No abstract available.
References
-
- Goldenberg RL, Iams JD, Mercer BM, Meis PJ, Moawad AH, Copper RL, et al. The preterm prediction study: the value of new vs. standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health 1998;88:233–8.
-
- Goldenberg RL, Iams JD, Das A, Mercer BM, Meis PJ, Moawad AH, et al. The preterm prediction study: sequential cervical length and fibronectin testing for the prediction of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 2000;182:636–43.
-
- Assessment of risk factors for preterm birth. ACOG Practice Bulletin No. 31. American College of Obstetricians and Gynecologists. Obstet Gynecol 2001;98:709–16.
-
- Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999;94:869–77.
-
- Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. Accuracy of cervicovaginal fetal fibronectin test in predicting risk of spontaneous preterm birth: systematic review. BMJ 2002;325:301–11.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials